AUPH - Aurinia Pharmaceuticals Inc Stock Price, Fair Value and News

$8.79-0.06 (-0.68%)

Delayed as of 25 Nov 2024, 02:00 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AUPH Price Action

Last 7 days

9.0%

Last 30 days

26.6%

Last 90 days

30.9%

Trailing 12 Months

-2.1%

AUPH RSI Chart

AUPH Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-56.19

Price/Sales (Trailing)

5.75

EV/EBITDA

248.43

Price/Free Cashflow

44.33

AUPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AUPH Fundamentals

AUPH Revenue

Revenue (TTM)

220.4M

Rev. Growth (Yr)

24.32%

Rev. Growth (Qtr)

18.5%

AUPH Earnings

Earnings (TTM)

-22.6M

Earnings Growth (Yr)

206.72%

Earnings Growth (Qtr)

1.9K%

AUPH Profitability

Operating Margin

87.25%

EBT Margin

-9.14%

Return on Equity

-5.81%

Return on Assets

-4.11%

Free Cashflow Yield

2.26%

AUPH Investor Care

Buy Backs (1Y)

0.30%

Diluted EPS (TTM)

-0.15

AUPH Alerts

Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	191.4M	207.1M	220.4M	0
2023	146.8M	160.1M	158.9M	175.5M
2022	66.3M	87.9M	129.0M	134.0M
2021	49.0M	47.9M	46.7M	45.6M
2020	318.0K	318.0K	25.2M	50.1M
2019	426.8K	390.5K	354.3K	318.0K
2018	429.3K	440.5K	451.8K	463.0K
2017	0	0	0	418.0K
2016	0	0	0	173.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

CEO	Mr. Peter S. Greenleaf M.B.A.
WEBSITE	auriniapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	300

Aurinia Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Aurinia Pharmaceuticals Inc? What does AUPH stand for in stocks?

AUPH is the stock ticker symbol of Aurinia Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aurinia Pharmaceuticals Inc (AUPH)?

As of Fri Nov 22 2024, market cap of Aurinia Pharmaceuticals Inc is 1.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AUPH stock?

You can check AUPH's fair value in chart for subscribers.

Is Aurinia Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AUPH is over valued or under valued. Whether Aurinia Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aurinia Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUPH.

What is Aurinia Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, AUPH's PE ratio (Price to Earnings) is -56.19 and Price to Sales (PS) ratio is 5.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aurinia Pharmaceuticals Inc's stock?

In the past 10 years, Aurinia Pharmaceuticals Inc has provided 0.088 (multiply by 100 for percentage) rate of return.